AngioGenex, Inc.
company.status.inactiveCIK 1085596fmd_0X9BSM97365D8SE3WA5BQ3CFNNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Jun 30, 2019, 12 periods
Latest annual · FY2018
Millions- Operating income
- (0)
- Net income
- (0)
Latest quarter · Q2 FY2019
Millions- Operating income
- (0)
- Net income
- (0)
AngioGenex, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2018 | FY2017 | Change | Source |
|---|---|---|---|---|
| Operating income | -$437,659 | -$646,188 | 10-K 2019-03-28 · proof | |
| Net income | -$435,448 | -$683,029 | 10-K 2019-03-28 · proof | |
| Cash from operating activities | -$453,789 | -$528,795 | 10-K 2019-03-28 · proof | |
| Total assets | $52,819 | $515,310 | -89.8% | 10-K 2019-03-28 · proof |
| Total liabilities | $1.1 million | $1.2 million | -4% | 10-K 2019-03-28 · proof |
| Cash and cash equivalents | $19,583 | $493,676 | -96% | 10-K 2019-03-28 · proof |
- What was AngioGenex, Inc.'s operating income in fiscal 2018?
- AngioGenex, Inc. reported operating income of -$437,659 for fiscal 2018 (the year ended Dec 31, 2018), against -$646,188 the year before. Source: the 10-K filed with the SEC on Mar 28, 2019. SEC
- What was AngioGenex, Inc.'s net income in fiscal 2018?
- AngioGenex, Inc. reported net income of -$435,448 for fiscal 2018 (the year ended Dec 31, 2018), against -$683,029 the year before. Source: the 10-K filed with the SEC on Mar 28, 2019. SEC
- What was AngioGenex, Inc.'s cash from operating activities in fiscal 2018?
- AngioGenex, Inc. reported cash from operating activities of -$453,789 for fiscal 2018 (the year ended Dec 31, 2018), against -$528,795 the year before. Source: the 10-K filed with the SEC on Mar 28, 2019. SEC
- What are AngioGenex, Inc.'s total assets?
- As of Dec 31, 2018, AngioGenex, Inc. reported total assets of $52,819, against $515,310 a year earlier (-89.8%). Source: the 10-K filed with the SEC on Mar 28, 2019. SEC
- What are AngioGenex, Inc.'s total liabilities?
- As of Dec 31, 2018, AngioGenex, Inc. reported total liabilities of $1.1 million, against $1.2 million a year earlier (-4%). Source: the 10-K filed with the SEC on Mar 28, 2019. SEC
- What are AngioGenex, Inc.'s cash and cash equivalents?
- As of Dec 31, 2018, AngioGenex, Inc. reported cash and cash equivalents of $19,583, against $493,676 a year earlier (-96%). Source: the 10-K filed with the SEC on Mar 28, 2019. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1085596&period_type=annual&limit=5"Information only, not investment advice.